{"nctId":"NCT02413398","briefTitle":"A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes","startDateStruct":{"date":"2015-06-15","type":"ACTUAL"},"conditions":["Type 2 Diabetes Mellitus"],"count":321,"armGroups":[{"label":"Dapagliflozin","type":"EXPERIMENTAL","interventionNames":["Drug: Dapagliflozin 10 mg"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo for Dapagliflozin"]}],"interventions":[{"name":"Dapagliflozin 10 mg","otherNames":["Farxiga™"]},{"name":"Matching Placebo for Dapagliflozin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female or male aged ≥18 years and \\<75 years.\n* History of T2DM for more than 12 months.\n* Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11%\n* Stable anti-diabetic treatment regimen\n* Renal impairment: CKD 3A\n\nExclusion Criteria:\n\n* Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.\n* History of diabetic ketoacidosis or hyperosmolar nonketotic coma.\n* Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110 mmHg\n* Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1:\n\nMyocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia.\n\n* History of any biopsy or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis.\n* Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency.\n* Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting insulins at screening.\n* Participation in another clinical study with an Investigational Product (IP) during the last 30 days prior to signing the consent at visit 1.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"74 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24","description":"To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\\^2). The \"number analyzed\" (142 dapaglifozin, 134 placebo) represents the number with change from baseline available at Week 24.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":"0.10"},{"groupId":"OG001","value":"-0.03","spread":"0.10"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Percent Change From Baseline in Total Body Weight at Week 24.","description":"To compare the mean percent change from baseline in total body weight between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\\^2). The \"number analyzed\" represents the number with change from baseline available at Week 24.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.42","spread":"0.32"},{"groupId":"OG001","value":"-2.02","spread":"0.32"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24.","description":"To compare the mean change from baseline in FPG between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\\^2). The \"number analyzed\" represents the number with change from baseline available at Week 24.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.46","spread":"5.20"},{"groupId":"OG001","value":"-4.87","spread":"5.13"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change From Baseline in Seated Systolic Blood Pressure (SBP) at Week 24.","description":"To compare the mean change from baseline in seated systolic blood pressure (SBP) between dapagliflozin 10 mg and placebo, after 24 weeks of oral administration of double-blind treatment in patients with type 2 diabetes, CKD stage 3A, and moderate renal impairment (CKD 3A; eGFR 45-59 mL/min/1.73m\\^2). The \"number analyzed\" represents the number with change from baseline available at Week 24.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"1.5"},{"groupId":"OG001","value":"-1.7","spread":"1.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":160},"commonTop":[]}}}